Last reviewed · How we verify

Niacin ER/Simvastatin Tablets

Abbott · Phase 3 active Small molecule

Niacin ER/Simvastatin combines extended-release niacin (which increases HDL and lowers triglycerides) with simvastatin (a statin that inhibits HMG-CoA reductase to lower LDL cholesterol).

Niacin ER/Simvastatin combines extended-release niacin (which increases HDL and lowers triglycerides) with simvastatin (a statin that inhibits HMG-CoA reductase to lower LDL cholesterol). Used for Hyperlipidemia and mixed dyslipidemia in patients requiring both statin and niacin therapy, Reduction of cardiovascular risk in patients with coronary heart disease.

At a glance

Generic nameNiacin ER/Simvastatin Tablets
Also known asABT-919/483, Niacin ER/Simvastatin, Simcor
SponsorAbbott
Drug classCombination lipid-modifying agent (statin + niacin)
TargetHMG-CoA reductase (simvastatin); GPR109A and DGAT2 (niacin)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Simvastatin blocks HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol production and hepatic VLDL secretion. Niacin ER acts through multiple mechanisms including inhibition of hepatic diacylglycerol acyltransferase-2 (DGAT2) and activation of GPR109A, leading to increased HDL cholesterol and reduced triglycerides. Together, they provide complementary lipid-modifying effects for cardiovascular risk reduction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: